Resource: FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
Source: U.S. Food and Drug Administration
Synopsis: The U.S. Food and Drug Administration issued an emergency use
Resource: The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro
Source: Antiviral Research
Synopsis: Although several clinical trials are now underway to test possible
Resource: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Source: New England Journal of Medicine
Summary: All persons who were newly vaccinated in a nationwide Israeli health
Resource: IDSA Guidelines on the Treatment and Management of Patients with COVID-19
Source: Infectious Disease Society of America
Synopsis: Among hospitalized adults with progressive severe* or
Resource: Utility of D-dimer in predicting venous thromboembolism in non-mechanically ventilated COVID survivors
Source: Thrombosis Research
Synopsis: Although D-dimer has been found to be a
Resource: SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination
Source: Society of Breast Imaging
Synopsis: SBI considerations for the management
Resource: COVID-19: Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting SARS-CoV-2 Infectivity
Source: U.S. Food and Drug Administration
Synopsis: The FDA
Resource: Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study
Source: Journal of Infection
Synopsis: 277 PCR-confirmed COVID-19 survivors were evaluated 10-14 weeks
Resource: Antithrombotic Therapy in Patients with COVID-19
Source: National Institutes of Health (NIH)
Synopsis: The above reference is a summary of recommendations from the NIH (last updated 12/17/20